ReviewCurrent pharmaceutical biotechnology2012
Attenuated oncolytic measles virus strains as cancer therapeutics.
Review in Current pharmaceutical biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Review
- Review
- Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.Current issues in molecular biology · 2025Review
- Insidious Insights: Implications of viral vector engineering for pathogen enhancement.Gene therapy · 2023Review
- Formulation for the Targeted Delivery of a Vaccine Strain of Oncolytic Measles Virus (OMV) in Hyaluronic Acid Coated Thiolated Chitosan as a Green Nanoformulation for the Treatment of Prostate Cancer: A Viro-Immunotherapeutic Approach.International journal of nanomedicine · 2023Article
- Screening of candidate genes associated with high titer production of oncolytic measles virus based on systems biology approach.Virus genes · 2022Article
- A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella.Molecular therapy oncolytics · 2022Article
- Mesenchymal stem cells as professional actors in gastrointestinal cancer therapy: From Naïve to genetically modified.Iranian journal of basic medical sciences · 2021Review
- Repurposing Infectious Diseases Vaccines Against Cancer.Frontiers in oncology · 2021Review
- Article
- Aeration and Shear Stress Are Critical Process Parameters for the Production of Oncolytic Measles Virus.Frontiers in bioengineering and biotechnology · 2019Article
- Fusogenic Viruses in Oncolytic Immunotherapy.Cancers · 2018Review
- Carrier Cells for Delivery of Oncolytic Measles Virus into Tumors: Determinants of Efficient Loading.Virologica Sinica · 2018Article
- Article
- New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.Biologics : targets & therapy · 2018Review
- Oncolytic Alphaviruses in Cancer Immunotherapy.Vaccines · 2017Review
- Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach.PloS one · 2017Article
- Replicon RNA Viral Vectors as Vaccines.Vaccines · 2016Review
- Oncolytic virotherapy for urological cancers.Nature reviews. Urology · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Attenuated measles virus vaccine strains have emerged as a promising oncolytic vector platform, having shown significant anti-tumor activity against a broad range of malignant neoplasms. Measles virus strains derived from the attenuated Edmonston-B (MV-Edm) vaccine lineage have been shown to selectively infect, replicate in and lyse cancer cells while causing minimal cytopathic effect on normal tissues. This review summarizes the preclinical data that led to the rapid clinical translation of oncolytic measles vaccine strains and provides an overview of early clinical data using this oncolytic platform. Furthermore, novel approaches currently under development to further enhance the oncolytic efficacy of MV-Edm strains, including strategies to circumvent immunity or modulate immune system responses, combinatorial approaches with standard treatment modalities, virus retargeting as well as strategies for in vivo monitoring of viral replication are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.